Pediatric Thrombotic Events: Incidence, Clinical Risk Factors and Outcome

Indian J Pediatr. 2019 Mar;86(3):241-244. doi: 10.1007/s12098-018-2827-5. Epub 2018 Dec 13.

Abstract

Objective: To study the incidence, clinical risk factors and outcome of thrombotic events in pediatric age group of 1 mo-12 y.

Methods: This prospective observational study was conducted in a tertiary care institute from September 2015 through October 2017. Forty nine children with thrombosis from 1 mo-12 y were enrolled.

Results: Out of 49 cases, 30 (61.2%) were due to venous thromboembolism (VTE) and 19 (38.8%) were of arterial thromboembolism (ATE). The cumulative average annual incidence for VTEs was found to be 38.2 (n = 30) and for ATEs it was found to be 24.2 (n = 19) per 10,000 hospital admissions over 2 y of study period. With total of 19 (38.7%), catheters were the leading cause of thrombosis followed by infection numbering to 10 cases (20.4%). Total 42.8% cases (n = 21) achieved complete resolution. Partial resolution was noted in 53.2% of cases (n = 26) and no resolution in 4% cases (n = 2). Total seven (14.3%) deaths were recorded during the study period.

Conclusions: The present study showed that thrombosis is an emerging problem in tertiary care setting adding to both mortality and morbidity in children. Central venous catheters followed by infection were the leading cause of thrombosis in this study.

Keywords: Incidence; Outcome; Pediatrics; Risk factor; Thrombosis.

Publication types

  • Observational Study

MeSH terms

  • Activated Protein C Resistance
  • Anticoagulants / therapeutic use
  • Antithrombin III
  • Child
  • Child, Preschool
  • Female
  • Heparin / therapeutic use
  • Heparin, Low-Molecular-Weight
  • Humans
  • Incidence
  • Infant
  • Male
  • Prospective Studies
  • Risk Factors
  • Thrombosis / diagnosis*
  • Thrombosis / drug therapy*
  • Thrombosis / etiology*
  • Treatment Outcome
  • Venous Thromboembolism
  • Venous Thrombosis
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Warfarin
  • Antithrombin III
  • Heparin

Supplementary concepts

  • Thrombophilia due to Activated Protein C Resistance